Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05362292 · ClinicalTrials.gov registry record · Phase 4
TReating Incontinence for Underlying Mental and Physical Health
A Phase 4 study of Urinary Incontinence and Overactive Bladder, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
- 2
- Study locations
NCT05362292: Recruiting Phase 4 study of Urinary Incontinence and Overactive Bladder, sponsored by University of California, San Francisco.
NCT05362292 is a Phase 4 study of Urinary Incontinence and Overactive Bladder that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 270 participants, roughly in line with the 256-participant average among 48 other Urinary Incontinence trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05362292, a Phase 4 study of Urinary Incontinence and Overactive Bladder, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
- 2
- Study locations
Study Summary
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.
Primary Outcome
The composite cognitive score will be calculated as the average of Z-scores from the following individual cognitive tests: a) Auditory Verbal Learning Test (AVLT); b) Oral Trail Making Test (OTMT) part A; c) OTMT part B; d) Digit Span Test; and e) Digit Symbol Substitution Test (DSST). The normative mean of each cognitive test will be subtracted from each participant's component test score, and this difference will be divided by the standard deviation for the appropriate normative sample. After
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mirabegron
- DRUG Tolterodine Tartrate ER
Study Locations (2)
California
- Stanford University - Palo Alto
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2027-08-02 |
| Phase | Phase 4 |
What NCT05362292 shows while recruiting
NCT05362292 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 256-participant average among 48 other Urinary Incontinence trials with a reported enrollment target.
The record links to 6 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05362292 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05362292 about?
NCT05362292 is a clinical study titled "TReating Incontinence for Underlying Mental and Physical Health". The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes i...
What is the current status of trial NCT05362292?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2022-10-04. Estimated completion is 2027-08-02.
What conditions does trial NCT05362292 study?
This clinical trial studies the following conditions: Urinary Incontinence, Overactive Bladder, Urinary Incontinence, Urge, Incontinence, Incontinence, Urinary.
What interventions are being tested in trial NCT05362292?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG), Tolterodine Tartrate ER (DRUG).
Who is sponsoring clinical trial NCT05362292?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05362292 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05362292's enrollment target sits among peer trials
270 14th of 48 higher than 35 of 48 other Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
COMPLETED · Phase 4
-
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
COMPLETED · Phase 4
-
NXT Post-Market Clinical Follow-up
RECRUITING
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI